CrossAssetDataThe Company File
···
ALKS

Alkermes plc

Alkermes plc is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in Dublin 4, IE. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $1.5 billion and a profit of $242 million (its filed statements).

Product business Pharmaceutical Preparations Dublin 4, IE filings since 2011 9 of 9 filed
Ask the desk about ALKS → Compare ALKS with INSM → Price chart on TradingView ↗ Full EDGAR file ↗ Watch ALKS →

Sector peers: INSMPTCTOPKSRPT

6.5/10headline grade
vs its business-model standard
6.7/10past 7.2/10present 5.4/10future

Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a product business: prior from its industry code (SEC 2834, Pharmaceutical Preparations); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.

The grade, in three tenses

Headline 6.5 out of ten, 9 of 9 metrics filed: past 6.7 out of ten, present 7.2 out of ten, future 5.4 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.

The nine metrics

  • Surviving crises (past): 8.2 out of ten. No warning events in its filings since 2017. 82nd percentile among 497 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Track record (past): 5.8 out of ten. +7.9% a year over 10 filed years; profitable in 3 of 10. 58th percentile among 324 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Shareholder treatment (past): 6.1 out of ten. Share count grew 1.0% a year. 15% of cash flow returned. Insiders: 34 sales, 0 purchases. 61st percentile among 80 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Financial health (present): 8.1 out of ten. ROE 13%: 13¢ of profit per shareholder dollar. Leverage 27%: owes 27¢ per asset dollar. 81st percentile among 472 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Industry position (present): 7.6 out of ten. top 24% of 314 in its family; net margin 16.4%. 76th percentile among 314 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Leadership (present): 4.6 out of ten. bottom 46% of 315 in its family for leadership. 46th percentile among 315 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
  • Room to expand (future): 5.8 out of ten. top 42% of 272 in its family for room to expand. 58th percentile among 272 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Growth drivers (future): 5.6 out of ten. top 44% of 307 in its family for growth drivers. 56th percentile among 307 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Expectations vs reality (future): 4.4 out of ten. bottom 44% of 234 in its family for expectations against reality. 44th percentile among 234 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).

The filing record

Newest annual report: Form 10-K filed 2026-02-25 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-07-28 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-07-28 (on EDGAR). Newest filing: Form 4, 2026-10-09. Filings on record since 2011. Read from EDGAR 2026-10-12.

Where the revenue comes from

Product and service lines in fiscal 2025: Vivitrol 32%, Aristada and Aristada Initio 25%, LYBALVI 24%, Royalty 17%, Manufacturing Revenue 3%. By geography: United States 93%, Foreign Country Excluding Specified Country 7%, Ireland under 1%. As tagged in its annual report (Form 10-K, filed 2026-02-25).

Who runs it

Jackson, Blair Curtis (President & CEO, Alkermes plc); Pops, Richard F (Director and CEO, Alkermes plc); Cooke, Shane (President, Alkermes plc); Reed, Joshua (SVP, Chief Financial Officer); Hopkinson, Craig C. (EVP R&D, Chief Medical Officer); Nichols, Christian Todd (SVP, Chief Commercial Officer); Gaffin, David Joseph (EVP, CLO, Alkermes, Inc.); Parisi, Samuel Joseph (VP, Finance (Interim PAO)); Whitaker, Anne Clem (director); Snyderman, Nancy Lynn Md (director); and 6 more. 16 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-10-09.

This file: Overview · Past · Present · Future · Filings · every company on file

Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.